Drugs / HGP1909
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04762407 | Nov 2020 → Feb 2021 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04652349 Comparator | Jul → Dec 2020 | hyperlipoproteinemia | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGP1909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652349 ↗ |